BioDelivery Sciences International, Inc. (NASDAQ:BDSI) CEO Sells $262,304.02 in Stock

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) CEO Herm Cukier sold 38,461 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $6.82, for a total transaction of $262,304.02. Following the completion of the sale, the chief executive officer now directly owns 74,842 shares in the company, valued at approximately $510,422.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shares of BDSI stock traded down $0.06 during midday trading on Wednesday, reaching $6.70. 1,116,894 shares of the stock were exchanged, compared to its average volume of 974,221. BioDelivery Sciences International, Inc. has a 1 year low of $2.80 and a 1 year high of $7.01. The firm has a market cap of $605.16 million, a PE ratio of -9.18 and a beta of 0.49. The company’s 50 day moving average is $5.91 and its two-hundred day moving average is $4.74. The company has a current ratio of 2.25, a quick ratio of 2.02 and a debt-to-equity ratio of 0.86.

BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings results on Tuesday, November 12th. The specialty pharmaceutical company reported $0.33 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.34. The company had revenue of $30.31 million during the quarter, compared to analysts’ expectations of $28.86 million. BioDelivery Sciences International had a negative return on equity of 8.80% and a negative net margin of 22.11%. As a group, equities analysts expect that BioDelivery Sciences International, Inc. will post 0.02 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Mackay Shields LLC lifted its position in BioDelivery Sciences International by 65.7% in the 3rd quarter. Mackay Shields LLC now owns 605,900 shares of the specialty pharmaceutical company’s stock valued at $2,551,000 after acquiring an additional 240,200 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of BioDelivery Sciences International by 1,019.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 186,409 shares of the specialty pharmaceutical company’s stock worth $867,000 after purchasing an additional 169,757 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of BioDelivery Sciences International during the second quarter valued at $1,395,000. River & Mercantile Asset Management LLP bought a new position in shares of BioDelivery Sciences International during the second quarter valued at $1,860,000. Finally, Northern Trust Corp boosted its position in shares of BioDelivery Sciences International by 39.8% during the second quarter. Northern Trust Corp now owns 258,748 shares of the specialty pharmaceutical company’s stock valued at $1,203,000 after buying an additional 73,637 shares during the last quarter. 69.44% of the stock is owned by institutional investors.

BDSI has been the subject of several recent analyst reports. BidaskClub raised shares of BioDelivery Sciences International from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 16th. LADENBURG THALM/SH SH raised their target price on BioDelivery Sciences International from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. ValuEngine raised BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research note on Tuesday. William Blair restated a “buy” rating on shares of BioDelivery Sciences International in a report on Tuesday, September 17th. Finally, TheStreet raised BioDelivery Sciences International from a “d” rating to a “c” rating in a research report on Friday, November 22nd. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $6.50.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Article: How mutual funds make money

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.